0 rating

Integrating Targeted Agents in Metastatic Colorectal Cancer

Marwan Fakih

Over the last 10 years there have been major improvements in the outcome of patients with metastatic colorectal cancer. The options for systemic chemotherapy in the US have expanded from variations in 5-fluorouracil (5-FU) scheduling to the integration of capecitabine, irinotecan, oxaliplatin, bevac-izumab, cetuximab, and panitumumab into the treatment paradigm. While combinations and sequences of cytotoxic chemotherapy have been optimized [118], the most effective use of molecular targeted agents remains to be determined.

Return to top


Our most popular articles